Stanley Laman Group Ltd. Purchases Shares of 1,002 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Stanley Laman Group Ltd. purchased a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 1,002 shares of the pharmaceutical company's stock, valued at approximately $486,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Mascagni Wealth Management Inc. purchased a new stake in shares of Vertex Pharmaceuticals in the fourth quarter valued at approximately $31,000. Truvestments Capital LLC boosted its position in shares of Vertex Pharmaceuticals by 30.3% during the 4th quarter. Truvestments Capital LLC now owns 99 shares of the pharmaceutical company's stock worth $40,000 after acquiring an additional 23 shares in the last quarter. Mpwm Advisory Solutions LLC acquired a new position in shares of Vertex Pharmaceuticals in the 4th quarter valued at $40,000. Midwest Capital Advisors LLC acquired a new stake in Vertex Pharmaceuticals during the 4th quarter worth $41,000. Finally, Minot DeBlois Advisors LLC acquired a new stake in Vertex Pharmaceuticals during the 4th quarter worth $44,000. Institutional investors own 90.96% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. Erste Group Bank downgraded Vertex Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Friday, May 23rd. Needham & Company LLC reaffirmed a "hold" rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. Leerink Partnrs lowered Vertex Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 6th. JPMorgan Chase & Co. increased their target price on Vertex Pharmaceuticals from $512.00 to $515.00 and gave the stock an "overweight" rating in a research report on Tuesday, May 6th. Finally, Morgan Stanley upped their price objective on shares of Vertex Pharmaceuticals from $462.00 to $464.00 and gave the stock an "equal weight" rating in a report on Tuesday, May 6th. Fourteen analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Vertex Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $515.04.

Vertex Pharmaceuticals Trading Down 1.0%

NASDAQ:VRTX traded down $4.61 during mid-day trading on Friday, hitting $455.45. The company had a trading volume of 1,021,326 shares, compared to its average volume of 1,417,847. The firm has a market cap of $116.96 billion, a P/E ratio of -207.02, a P/E/G ratio of 2.11 and a beta of 0.41. The business's fifty day moving average is $462.54 and its two-hundred day moving average is $460.16. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.35 and a current ratio of 2.69. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $377.85 and a fifty-two week high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 EPS for the quarter, missing the consensus estimate of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. The firm had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.85 billion. During the same period in the prior year, the business earned $4.76 earnings per share. Vertex Pharmaceuticals's quarterly revenue was up 2.6% compared to the same quarter last year. As a group, research analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.